Nivolumab Improves Survival in Advanced Esophageal Cancer

Nivolumab (Opdivo) extended overall survival (OS) compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC), according to findings from the phase III ATTRACTION-3 study presented at the 2019 ESMO Congress.1

https://www.onclive.com/conference-coverage/esmo-2019/nivolumab-improves-survival-in-advanced-esophageal-cancer

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *